Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 4/2021

Open Access 01-04-2021 | Fabry Disease | Cornea

Corneal densitometry: a potential indicator for early diagnosis of Fabry disease

Authors: Senmao Li, Robert Siggel, Yongwei Guo, Niklas Loreck, Alexander C. Rokohl, Christine Kurschat, Ludwig M. Heindl

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 4/2021

Login to get access

Abstract

Purpose

To assess corneal densitometry in patients with Fabry disease (FD) and to compare corneal densitometry differences in FD patients to different corneal manifestations.

Methods

Ten participants (20 eyes) with FD and 10 age-matched healthy volunteers (20 eyes) were recruited. All participants were assessed by standardized ophthalmic examinations and the corneal densitometry analysis by Pentacam HR. Densitometry measurements were analyzed in standardized grayscale units.

Results

Seven patients developed conjunctival vessel tortuosity, cornea verticillata appeared in 6 patients, and two patients had Fabry cataract. Retinal vessel tortuosity occurred in 4 patients, and dilation of retinal vessels appeared in 3 patients, all symptoms occurred in both eyes. The first diagnosis of FD up to examination was 4.7 ± 3.23 years, and first ERT up to examination was 2.6 ± 2.27 years. The initial time to diagnosis was negatively related to the corneal densitometry value of the 0–2-mm (r = − 0.556, p = 0.011) and 2–6-mm (r = − 0.482, p = 0.032) zones in the posterior layer. FD group have significantly higher corneal densitometry in anterior 0–2-mm zone and 2–10-mm zone anterior and posterior layer than the control group (p ≤ 0.035, respectively). When divided into two groups by the existence of cornea verticillata, there was a statistically significant difference in the anterior layer, 6–10-mm zone (p = 0.031); in the central layer, 0–2 mm (p = 0.012), 2–6 mm (p = 0.001), 6–10 mm (p = 0.002), and total (p = 0.002); and in the posterior layer, 6–10 mm (p = 0.004) and total (p = 0.002).

Conclusions

FD patients show higher corneal densitometry, and corneal densitometry may have potential for early diagnosis and reminding progress of FD.
Literature
1.
2.
go back to reference Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, Maillot F, Serratrice C, Masseau A, Chérin P (2012) Fabry disease ‘the new great imposter’: results of the French observatoire in internal medicine departments (FIMeD). Clin Genet 81(6):571–577CrossRef Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, Maillot F, Serratrice C, Masseau A, Chérin P (2012) Fabry disease ‘the new great imposter’: results of the French observatoire in internal medicine departments (FIMeD). Clin Genet 81(6):571–577CrossRef
3.
go back to reference Desnick R, Ioannou Y, Eng C (2001) Fabry disease: a-galactosidase A deficiency. Metabolic and molecular bases of inherited disease New York: McGraw-Hill:3733–3774 Desnick R, Ioannou Y, Eng C (2001) Fabry disease: a-galactosidase A deficiency. Metabolic and molecular bases of inherited disease New York: McGraw-Hill:3733–3774
4.
go back to reference Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. Jama 281(3):249–254CrossRef Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. Jama 281(3):249–254CrossRef
6.
go back to reference Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 285(21):2743–2749CrossRef Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 285(21):2743–2749CrossRef
7.
go back to reference Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U (2017) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54(4):288–296. https://doi.org/10.1136/jmedgenet-2016-104178CrossRefPubMed Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U (2017) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54(4):288–296. https://​doi.​org/​10.​1136/​jmedgenet-2016-104178CrossRefPubMed
8.
go back to reference Spaeth G, Frost P (1965) Fabry’s disease: its ocular manifestations. Arch Ophthalmol 74(6):760–769CrossRef Spaeth G, Frost P (1965) Fabry’s disease: its ocular manifestations. Arch Ophthalmol 74(6):760–769CrossRef
9.
go back to reference Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry’s disease. Arch Ophthalmol 97(4):671–676CrossRef Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry’s disease. Arch Ophthalmol 97(4):671–676CrossRef
10.
go back to reference Orssaud C, Dufier JL, Germain DP (2003) Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24(3):129–139CrossRef Orssaud C, Dufier JL, Germain DP (2003) Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24(3):129–139CrossRef
11.
go back to reference Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol 33(2):164–168CrossRef Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol 33(2):164–168CrossRef
12.
go back to reference Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S (2007) Ocular manifestations of Fabry’s disease: data from the Fabry outcome survey. Br J Ophthalmol 91(2):210–214CrossRef Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S (2007) Ocular manifestations of Fabry’s disease: data from the Fabry outcome survey. Br J Ophthalmol 91(2):210–214CrossRef
13.
go back to reference Fumex-Boizard L, Cochat P, Fouilhoux A, Guffon N, Denis P (2005) Relation between ocular manifestations and organ involvement in ten patients with Fabry disease. Journal francais d’ophtalmologie 28(1):45–50CrossRef Fumex-Boizard L, Cochat P, Fouilhoux A, Guffon N, Denis P (2005) Relation between ocular manifestations and organ involvement in ten patients with Fabry disease. Journal francais d’ophtalmologie 28(1):45–50CrossRef
14.
go back to reference Dufier J, Gubler M, Dhermy P, Lenoir G, Paupe J, Haye C (1980) Fabry’s disease in ophthalmology (author’s transl). Journal francais d’ophtalmologie 3(11):625–630PubMed Dufier J, Gubler M, Dhermy P, Lenoir G, Paupe J, Haye C (1980) Fabry’s disease in ophthalmology (author’s transl). Journal francais d’ophtalmologie 3(11):625–630PubMed
15.
go back to reference Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine 8(9):539CrossRef Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genetics in Medicine 8(9):539CrossRef
16.
go back to reference Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53(4):416–423CrossRef Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53(4):416–423CrossRef
17.
go back to reference Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG (2017) Drug-induced corneal epithelial changes. Survey of ophthalmology 62 (3):286-301 Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, Ulrich RG (2017) Drug-induced corneal epithelial changes. Survey of ophthalmology 62 (3):286-301
18.
go back to reference Bishop DF, Kornreich R, Desnick RJ (1988) Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’untranslated region. Proc Natl Acad Sci 85(11):3903–3907CrossRef Bishop DF, Kornreich R, Desnick RJ (1988) Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’untranslated region. Proc Natl Acad Sci 85(11):3903–3907CrossRef
19.
go back to reference Masson C, Cissé I, Simon V, Insalaco P, Audran M (2004) Fabry disease: a review. Joint Bone Spine 71(5):381–383CrossRef Masson C, Cissé I, Simon V, Insalaco P, Audran M (2004) Fabry disease: a review. Joint Bone Spine 71(5):381–383CrossRef
20.
go back to reference Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307CrossRef
21.
go back to reference Davey PG (2014) Fabry disease: a survey of visual and ocular symptoms. Clinical Ophthalmology (Auckland, NZ) 8:1555 Davey PG (2014) Fabry disease: a survey of visual and ocular symptoms. Clinical Ophthalmology (Auckland, NZ) 8:1555
22.
go back to reference Otri AM, Fares U, Al-Aqaba MA, Dua HS (2012) Corneal densitometry as an indicator of corneal health. Ophthalmology 119(3):501–508CrossRef Otri AM, Fares U, Al-Aqaba MA, Dua HS (2012) Corneal densitometry as an indicator of corneal health. Ophthalmology 119(3):501–508CrossRef
23.
go back to reference Leonardi A, Carraro G, Modugno RL, Rossomando V, Scalora T, Lazzarini D, Calò L (2019) Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. Br J Ophthalmol 104(5):718–722CrossRef Leonardi A, Carraro G, Modugno RL, Rossomando V, Scalora T, Lazzarini D, Calò L (2019) Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. Br J Ophthalmol 104(5):718–722CrossRef
24.
go back to reference Alnawaiseh M, Zumhagen L, Zumhagen S, Schulte L, Rosentreter A, Schubert F, Eter N, Mönnig G (2016) Corneal densitometry as a novel technique for monitoring amiodarone therapy. Ophthalmology 123(11):2294–2299CrossRef Alnawaiseh M, Zumhagen L, Zumhagen S, Schulte L, Rosentreter A, Schubert F, Eter N, Mönnig G (2016) Corneal densitometry as a novel technique for monitoring amiodarone therapy. Ophthalmology 123(11):2294–2299CrossRef
25.
go back to reference Schaub F, Enders P, Bluhm C, Bachmann BO, Cursiefen C, Heindl LM (2017) Two-year course of corneal densitometry after descemet membrane endothelial keratoplasty. Am J Ophthalmol 175:60–67CrossRef Schaub F, Enders P, Bluhm C, Bachmann BO, Cursiefen C, Heindl LM (2017) Two-year course of corneal densitometry after descemet membrane endothelial keratoplasty. Am J Ophthalmol 175:60–67CrossRef
26.
go back to reference Schaub F, Gerber F, Adler W, Enders P, Schrittenlocher S, Heindl LM, Cursiefen C, Bachmann BO (2019) Corneal densitometry as a predictive diagnostic tool for visual acuity results after descemet membrane endothelial keratoplasty. Am J Ophthalmol 198:124–129CrossRef Schaub F, Gerber F, Adler W, Enders P, Schrittenlocher S, Heindl LM, Cursiefen C, Bachmann BO (2019) Corneal densitometry as a predictive diagnostic tool for visual acuity results after descemet membrane endothelial keratoplasty. Am J Ophthalmol 198:124–129CrossRef
27.
go back to reference Dhubhghaill SN, Rozema JJ, Jongenelen S, Hidalgo IR, Zakaria N, Tassignon M-J (2014) Normative values for corneal densitometry analysis by Scheimpflug optical assessment. Invest Ophthalmol Vis Sci 55(1):162–168CrossRef Dhubhghaill SN, Rozema JJ, Jongenelen S, Hidalgo IR, Zakaria N, Tassignon M-J (2014) Normative values for corneal densitometry analysis by Scheimpflug optical assessment. Invest Ophthalmol Vis Sci 55(1):162–168CrossRef
28.
go back to reference Tekin K, Sekeroglu MA, Kiziltoprak H, Yilmazbas P (2017) Corneal densitometry in healthy corneas and its correlation with endothelial morphometry. Cornea 36(11):1336–1342CrossRef Tekin K, Sekeroglu MA, Kiziltoprak H, Yilmazbas P (2017) Corneal densitometry in healthy corneas and its correlation with endothelial morphometry. Cornea 36(11):1336–1342CrossRef
Metadata
Title
Corneal densitometry: a potential indicator for early diagnosis of Fabry disease
Authors
Senmao Li
Robert Siggel
Yongwei Guo
Niklas Loreck
Alexander C. Rokohl
Christine Kurschat
Ludwig M. Heindl
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Keyword
Fabry Disease
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 4/2021
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-05027-6

Other articles of this Issue 4/2021

Graefe's Archive for Clinical and Experimental Ophthalmology 4/2021 Go to the issue